Avedro, Inc.

📍 Waltham, United States👥 76 employees💰 Last funded Sep 2017
Pharmaceuticals🌐 avedro.com
Website LinkedIn
Avedro is a leading commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses. Avedro’s proprietary Avedro Corneal Remodeling Platform strengthens, stabilizes and reshapes the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. The Avedro Corneal Remodeling Platform is comprised of Avedro’s KXL and Mosaic systems, each of which delivers ultraviolet A light, and a suite of proprietary single-use riboflavin drug formulations, which, when applied together to the cornea, induce a biochemical reaction called corneal collagen cross-linking.
3
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
3
Investor activity2013–2017 · investors recorded per year
201312015120171
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Avedro, Inc.?
Avedro, Inc. has 3 investors on record on gritt.io.
When did Avedro, Inc. last raise funding?
The most recent investment in Avedro, Inc. recorded on gritt.io was in September 2017.
What industry is Avedro, Inc. in?
Avedro, Inc. operates in Pharmaceuticals. Find similar Pharmaceuticals investors on gritt.io.
Where is Avedro, Inc. based?
Avedro, Inc. is headquartered in Waltham, United States.